 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...56789101112131415...3637» |
- |||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
ATLA-3. No difference in PFS post crizotinib between Brigatinib (19.3m) vs. Alectinib (19.2m). @ALKpositiveINT @ALKLungCancer @lungcancertalk @LCAM_org (Twitter) - Dec 2, 2022
- || Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
#ESMOAsia22 #Brigatinib vs #Alectinib in #Crizotinib refractory #ALK + NSCLC (Twitter) - Dec 1, 2022
- ||| Xalkori (crizotinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
ALTA-3 results Brigatinib vs Alectinib after crizotinib progression. At interim analysis there was no signal of diff activity and study was stopped. #ESMOAsia22 (Twitter) - Dec 1, 2022
- | Alecensa (alectinib) / Roche
Journal: A reduced dosing strategy can work for Alectinib in ALK rearranged non small cell lung cancer. (Pubmed Central) - Nov 30, 2022
No abstract available
- ||| Alecensa (alectinib) / Roche
Adverse events: What do you think of switching from Alectinib due to heavy side effects even though Alectinib is working well? (Twitter) - Nov 29, 2022
- |||| Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/BFljX1kxWD (Twitter) - Nov 22, 2022
- || Alecensa (alectinib) / Roche
Clinical data, Journal, Real-world evidence: Special issue "The advance of solid tumor research in China": Real-world clinical outcomes of alectinib for advanced non-small-cell lung cancer patients with ALK fusion in China. (Pubmed Central) - Nov 22, 2022
In addition, we found that "crizotinib pretreatment", "liver metastasis", and "TP53 co-mutation" were individually associated with shorter PFS in alectinib treatment. In conclusion, this study confirms the salient clinical outcomes of alectinib for ALK-fusion-driven NSCLC patients with or without brain metastases, adding real-world evidence to the priority of alectinib in clinical practice.
- | Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
Journal: Observation of Alectinib- and Crizotinib- included chemotherapy in children with ALK-positive anaplastic large cell lymphoma: A single institutional experience. (Pubmed Central) - Nov 22, 2022
Though a relatively small case number, this study raised the possibility that alectinib-included therapeutic regimens may benefit the early response, in-depth molecular remission, and persistent remission to some extent. Further studies are warranted to validate our preliminary findings.
- ||| Alecensa (alectinib) / Roche
Clinical, Adverse events: Patient: doctor, please tell me the exact probability that I have an ALK mutation and also the 12th most common side effect of alectinib. And if you look it up on the computer, I'll never trust you again. (Twitter) - Nov 21, 2022
- || Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical, Retrospective data, Review, Journal: First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis. (Pubmed Central) - Nov 19, 2022
Lorlatinib was associated with the best PFS overall, and was suitable for patients with or without brain metastases. Brigatinib was associated with the best PFS in Asian patients.
- || Alecensa (alectinib) / Roche
more advertisers: @StateFarm @DoorDash @Hyundai @bloodvesselsnft @MGMNatlHarbor @DKSportsbook @buzznet @SearchingMovie @thepennyhoarder @MerrillLynch @toyist_zone @GarloGenius @DoveMenCare @salesforce @littlecaesars @Nreal @AlecensaHCP @peacock @BayerUS @Novavax @DeloitteUS (Twitter) - Nov 18, 2022
- | Alunbrig (brigatinib) / Takeda
Trial completion date, Metastases: ALTA-2: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (clinicaltrials.gov) - Nov 16, 2022
P2, N=103, Active, not recruiting, Sponsor: Ariad Pharmaceuticals
Brigatinib was associated with the best PFS in Asian patients. Trial completion date: Oct 2022 --> Jun 2023
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Retrospective data, Journal: Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study. (Pubmed Central) - Nov 15, 2022
This study provides a unique overview of the patient population treated with ALK TKI in Sweden and reveals the treatment patterns applied in real clinical practice. More research is needed when longer follow-up data are available for later-generation ALK TKI, to fully understand ALK TKI sequencing and its effect on patient survival in a real-world setting.
- ||| Alecensa (alectinib) / Roche
Review, Journal, Adverse events: Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib. (Pubmed Central) - Nov 15, 2022
Safety and tolerability data from the first-line phase III alectinib trials are also consistent with those observed in clinical trials of alectinib in later-line settings. These results add to the weight of evidence recommending alectinib as a preferred therapy for treatment-naive advanced ALK-positive NSCLC.
- |||| Alecensa (alectinib) / Roche
Clinical: Super accompanying editorial by Maurice Perol, outlining key issues: - likely best intracranial efficacy of ALK TKIs - duration of CNS toxicity is relevant, as longterm low grade CNS Tox has impact - alectinib & brig continue to be 1L options https://t.co/QDdvIEAkTF @OncoAlert (Twitter) - Nov 13, 2022
- |||| Alecensa (alectinib) / Roche
Clinical, Adverse events: Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell #lungcancer receiving alectinib. Pls. visit @ESMO_Open by @myESMO https://t.co/WD7MOZ3Qot (Twitter) - Nov 12, 2022
- |||| Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Clinical, Real-world evidence: Assessment of Alectinib vs Ceritinib in ALK-Positive NSCLC in Phase 2 Trials and Real-world Data https://t.co/pBY9UPRVDs via @JAMANetworkOpen part of @JAMANetwork (Twitter) - Nov 8, 2022
- ||| Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Awesome #TumorBoardTuesday by @LeciaSequist discussing #ALK fusion+ #NSCLC Chooing #TKI: 🧠 mets > Lorlatinib vs Brigatinib, NO 🧠 mets > Alectinib vs Btigatinib, type of #mutation_matters #LCAM #LCSM @ALKLungCancer @TumorBoardTues (Twitter) - Nov 4, 2022
- ||||| Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
📅El día de hoy en SMeO 2022 @SMEOMX el Dr. Cabrera @DrLuisCM presentó Estudio Fase II con Alectinib en combinación con Bevacizumab como primera línea de tratamiento 🫁🤩, estudio que se presentó también en ASCO por el Dr. Arrieta @ogarrieta. #UFOT #CancerResearch #SMeO #ALEKB (Twitter) - Nov 3, 2022
- | Lorbrena (lorlatinib) / Pfizer
Journal, Tumor Mutational Burden, IO biomarker: Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report. (Pubmed Central) - Nov 2, 2022
Despite early progression within 3 mo under crizotinib, a durable response was achieved with alectinib...Another rebiopsy revealed ALK:p.L1196M, but the tumor did not respond to brigatinib or carboplatin/pemetrexed, before stabilization under lorlatinib...Lorlatinib retained efficacy in the heavily pretreated setting, while its upfront use could possibly have prevented the stepwise emergence of compound ALK mutations. Furthermore, the disease course was more aggressive and OS shorter compared to the V2/TP53wt ALK+ lung adenocarcinoma, while crizotinib, ceritinib and brigatinib did not confer the benefit expected according to NGS results, which also underline the need for more potent drugs against ALK in the high-risk setting of neuroendocrine histology.
- || Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
I prefer Alectinib, brigatinib is an option , lorlatinib had a neurological toxicity (Twitter) - Nov 1, 2022
- || Lorbrena (lorlatinib) / Pfizer, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
🙋♂️ trial eponyms (❁´◡`❁) Alectinib, ALEX Brigatinib, ALTA-1L Certinib, ASCEND4 Lorlatinib, CROWN (Twitter) - Nov 1, 2022
- || Ceritinib is rarely used due to toxicity. Tend to start with alectinib or brigatinib then at progression or high volume brain involvement, switch to lorlatinib. I think ALTA3 showed alectinib was no better than brigatinib. (Twitter) - Nov 1, 2022
- ||| Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Head-to-Head: how do you decide between Brigatinib vs Alectinib vs Ceritinib? if none were compared head-to-head? 🤯 (Twitter) - Nov 1, 2022
- ||||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Clinical: 12/17 #TumorBoardTuesday Back to our case🔎 👨🏽💼After 3 years on alectinib, cancer progressed 💉Bx = new ALK I1171N ➡️ patient rx’d lorlatinib 🤔Different sensitivity of each TKI to each ALK resistance mutation was mapped in 💫 landmark 📚@JustinGainor @CD_AACR paper. (Twitter) - Nov 1, 2022
- |||| Xalkori (crizotinib) / Pfizer, Alecensa (alectinib) / Roche
10/17 #TumorBoardTuesday #LCSM 👩🏻⚕️ Mini tweetorial 6 ALK treatment 📌Alectinib ✨ALEX trial✨ ♦️For those w/o prior CNS mets, CNS PD at 1 year: 🔸31% on crizotinib 💥only 5% on alectinib 📚@gadgeel @Annals_Oncology 2018 (Twitter) - Nov 1, 2022
- Alecensa (alectinib) / Roche
Phase 1/2a Study Evaluating Alectinib Pharmacokinetics and Efficacy in Hispanic Population with Advanced ALK-rearranged Non-Small-Cell Lung Cancer. () - Nov 1, 2022 - Abstract #IASLCACLC2022IASLC_ACLC_57;
Conclusions : Alectinib PK analysis in the Hispanic population demonstrated significant variation and was effective and safe with a 300 mg twice-daily dose. This study suggests that an individualized dose guided by plasmatic concentrations might be attractive to optimize therapy, improving access and avoiding unnecessary toxicity without compromising clinical outcomes.
- |||| Imfinzi (durvalumab) / AstraZeneca, Alecensa (alectinib) / Roche
6/7: 21. More LDCT screening: https://t.co/Jo6aKmM3JV 22. Durvalumab for stage III: https://t.co/gzTDdmTWna 23. Alectinib: https://t.co/tkufygfwjc 24. Nodal staging & pharma: https://t.co/O57UBAgn1p 25. Adj chemo for who: https://t.co/53LeyYTs2s @lcfamerica @ALKLungCancer (Twitter) - Oct 31, 2022
- || Alecensa (alectinib) / Roche
I have a similar case. I had to switch from alectinib to lorla because of lung tox (after break), then carbo/pem-> pem on progression. Not only did they have a longer response, tolerated it much better. (Twitter) - Oct 26, 2022
- | Journal: Cancer Therapy Targeting Fusion Genes in Lung Cancer (Pubmed Central) - Oct 26, 2022
When limited to fusion genes, as of June 2022, crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib are approved for the ALK fusion gene; crizotinib and entrectinib for the ROS1 fusion gene; selpercatinib for the RET fusion gene; entrectinib and larotrectinib for the NTRK fusion gene have been approved in Japan. This article summarizes the therapeutic development of each fusion gene mutation, as well as the therapeutic outcomes and adverse events of the approved drugs.
- |||| pemetrexed / Generic mfg., Alecensa (alectinib) / Roche
Stage IV ALK+ Lung adenocarcinoma 1L Alectinib: PR lasting 16 months 2L Carbo-pem —> pemetrexed (on course #41): ongoing response +26 months. #lcsm cc: @SyedMAhmedMDPhD (Twitter) - Oct 26, 2022
- Alecensa (alectinib) / Roche
Primary Intraosseous Rhabdomyosarcoma: Report of Two Cases () - Oct 24, 2022 - Abstract #AMP2022AMP_523;
RMS are malignant mesenchymal tumors with skeletal muscle differentiation, currently classified into embryonal, alveolar, pleomorphic, and spindle/sclerosing types. Recent advances in molecular diagnostics have led to identification of a rare type of RMS defined by a recurrent genomic abnormality and distinct clinicopathologic features.
- Post-Therapy Samples Collected through Rapid Tissue Donation Confirms the Necessity of Tissue-Based NextGeneration Sequencing in Identifying Driver Mutations () - Oct 24, 2022 - Abstract #AMP2022AMP_317;
Collection and sequencing of RTD samples provides an opportunity to detect resistance mutations and to understand more about post-treatment disease progression and tumor heterogeneity. The identification of drivers by comprehensive NGS tissue testing in two cases serves as a reminder about the value of such testing when no drivers are identified by small panels or blood-based NGS testing.
- | Journal, HEOR, Real-world evidence: Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer. (Pubmed Central) - Oct 23, 2022
Clinically relevant toxicities occurred across all ALK-TKIs. Treatment modifications due to toxicity may not necessarily compromise outcomes, allowing multiple approaches to deal with ALK-TKI toxicities.
- |||| Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Retrospective data: Retrospective, not-randomized study on lorlatinib vs chemo in first-line alectinib resistant patients. Interestingly, patients who experienced early progression (within 1 y) during alectinib did better with chemo vs lorla. Overall no PFS or OS differences. https://t.co/Tg7oSZTQ4s (Twitter) - Oct 22, 2022
- || Alecensa (alectinib) / Roche
If off label cDNA after chemo XRT comes back +, would you start Osi or Alectinib? at least from a CNS control standpoint? (Twitter) - Oct 21, 2022
- ||| Alecensa (alectinib) / Roche
50s, EML4-ALK fusion, pdl1 30%, brain Mets on present. Started alectinib, favorable response. Cns only progression 1 y later tx SBRT, 3 m later wider brain progression and systemic progression. After WBRT? @JackWestMD @mjfidler @PatelOncology @LeciaSequist @ChristineBestv1 (Twitter) - Oct 21, 2022
- || Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
The toxicity of Lorlatinib is an issue but seems to be easily managed. Interestingly a poll on the world wide ALK forum asking those who have been on both Alectinib and Lorlatinib which they preferred.Almost twice as many preferred Lorlatinib. (Twitter) - Oct 20, 2022
- | Alecensa (alectinib) / Roche
Journal: A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis. (Pubmed Central) - Oct 20, 2022
Given the increasing application of the ALK-tyrosine kinase inhibitors (TKIs), it is extremely crucial to define the patients who could be suitable for this treatment in clinic. The present case has provided supporting evidence that noncanonical ALK rearrangements on the genomic level are often functionally relevant and targetable by ALK-TKI, particularly in cases with sub-optimal quantity and quality for RNA validation.
- || Alecensa (alectinib) / Roche
Well that’s a fascinating poll outcome! Alectinib remains preferred. Slowly, Lorla brain data is convincing some. Intrigued that brig hasn’t carved this niche as I recall messaging that this was its USP. My personal prescribing still favours alectinib. Lorla prob better but tox. (Twitter) - Oct 20, 2022
- EFFICACY, SAFETY AND BRAIN METASTASES CONTROL OF FIRST-LINE TREATMENT STRATEGIES FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE NON-SMALL CELL LUNG CANCER: A NETWORK META-ANALYSIS (Tiziano Room 1) - Oct 19, 2022 - Abstract #AIOM2022AIOM_8;
Patients received eight different treatments: alectinib (300 mg and 600 mg), brigatinib, ceritinib, crizotinib, ensartinib, lorlatinib, and chemotherapy. In our network meta-analysis, alectinib and lorlatinib resulted the therapeutics with the highest probability to be the best first-line options for ALK-rearranged NSCLC patients ensuring prolonged disease control.
- | Alecensa (alectinib) / Roche
Observational data, Retrospective data, Journal, Real-world evidence: Real world use of radiation for newly diagnosed brain metastases in ALK-positive lung cancer receiving a first line ALK inhibitor. (Pubmed Central) - Oct 19, 2022
We found decreasing use of CNS-directed RT in patients with NSCLC with new BM on first-line ALK inhibitors. Clinical outcomes for these patients require continued investigation, because physicians may become increasingly comfortable deferring upfront local therapy for BM in lieu of novel targeted agents with improved CNS activity.
- | Alecensa (alectinib) / Roche
Journal: Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report. (Pubmed Central) - Oct 19, 2022
This is the first report of a lung adenocarcinoma patient harbouring a new uncommon anaplastic lymphocyte kinase fusion that showed a remarkable response to alectinib. NGS aids in selecting treatment in non-small cell lung cancer patients.
- | Alecensa (alectinib) / Roche
Journal: Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib. (Pubmed Central) - Oct 19, 2022
This case suggests that for patients with rare or complex EML4-ALK fusions at DNA level, additional RNA-NGS is necessary to verify its functionality as early as possible. Targeting EML4-ALK firstly may be more preferable despite the coexisting of BRAF V600E.
- || Review, Journal: ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. (Pubmed Central) - Oct 19, 2022
Across these counties, next-generation TKIs are preferred for patients with progressing BM lesions. Although next-generation ALK TKIs demonstrate significant activity in these patients and following progression on crizotinib, access remains a challenge for personalized therapy.
- ||| Enrollment open, Tumor mutational burden, Metastases: KOSMOSII: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II (clinicaltrials.gov) - Oct 17, 2022
P=N/A, N=1000, Recruiting, Sponsor: Seoul National University Bundang Hospital
Although next-generation ALK TKIs demonstrate significant activity in these patients and following progression on crizotinib, access remains a challenge for personalized therapy. Not yet recruiting --> Recruiting
- Alecensa (alectinib) / Roche
ALECTINIB-RELATED ERYTHROCYTE MEMBRANE CHANGES, NON-IMMUNE HEMOLYSIS AND ERYPTOSIS () - Oct 16, 2022 - Abstract #EHOC2022EHOC_79;
Patients predominantly showed mild anemia, but one patient developed significant Coombs-negative hemolysis. In this case, hemolytic markers improved after alectinib was discontinued.
- |||| Zykadia (ceritinib) / Novartis, Alunbrig (brigatinib) / Takeda, Alecensa (alectinib) / Roche
Clinical: Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2) https://t.co/PVbPEodjYI (Twitter) - Oct 13, 2022
- | Journal, HEOR: Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China. (Pubmed Central) - Oct 11, 2022
For Chinese patients with advanced ALK-positive NSCLC, ensartinib was a cost-effective option compared with crizotinib, and was a dominant alternative to ceritinib and brigatinib. Although lorlatinib and alectinib were associated with prolonged survival compared with ensartinib, they were less cost-effective than ensartinib due to the overwhelming total costs.
- Lorbrena (lorlatinib) / Pfizer, Alecensa (alectinib) / Roche
Treatment of ALK positive metastatic adenocarcinoma lung - A case report of sequencing therapy. (Exhibition / Poster Area) - Oct 9, 2022 - Abstract #ESMOAsia2022ESMO_Asia_977;
Molecular testing and looking for ALK resistance mutation helps to choose Lorlatinib, the only sensitive TKI which targets (G1202R). This is an evolving precision based therapy, improves outcome in lung cancer.